Even when the use of atezolizumab was restricted to patients with high PDL1 expression (on 50% or more of tumour cells or 10% or more of tumour-infiltrating immune cells), the ICER remained high at US$464,703 gained per QALY gained. The gene discussed is CD274; the disease is neoplasm.